Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2013

View Archived Issues

Uncovering the mechanism of action of a potent, small-molecule inhibitor of human prostate cancer

mRNA-mediated inhibition of transcription improves cardiovascular disease-related etiologies

PurGenesis' phase IIa trial of PUR-0110 in ulcerative colitis meets primary endpoint

A small-molecule design strategy for increasing the potency of RNA-targeting compounds

Telormedix receives funding for new psoriasis treatment

Lupin acquires exclusive U.S. rights to Alinia from Romark

Evidence for the success of a DNA vaccine against AD in non-human primates

PTC Therapeutics selects candidate for spinal muscular atrophy collaboration

Quantification of serum glucose levels demonstrated with NMR assay

First patient dosed in phase IIa part of ATU-027 combination study

FDA grants orphan drug status to E-7777 for cutaneous T-cell lymphoma

Cleveland BioLabs and Incuron begin phase I trial of CBL-0137 in the U.S.

Keryx Biopharmaceuticals submits NDA for Zerenex

Ajinomoto presents new TRPA1 antagonists

Duke University patents novel vaccines for the treatment of cancer

NuMe Health changes name to MicroBiome Therapeutics

Vaccines for tularemia disclosed by Albany Medical Center

European license for Velcade extended

New agents for cancer patented by Shanghai Allist Pharmaceuticals

Lu-AE-58054 is a safe and effective add-on therapy to acetylcholinesterase inhibitors

Threshold commences phase II study of hypoxia-targeted drug in advanced melanoma

GSK to discontinue manufacture and sale of Bexxar anticancer regimen

Teva obtains European approval for Lonquex to help manage neutropenia during chemotherapy

Benitec and University of New South Wales execute license agreement for Tribetarna program

Pomalidomide approved by European Commission for multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...